Literature DB >> 27122971

Research output and the public health burden of cancer: is there any relationship?

F M Patafio1, S C Brooks2, X Wei1, Y Peng3, J Biagi1, C M Booth4.   

Abstract

PURPOSE: The relative distribution of research output across cancer sites is not well described. Here, we evaluate whether the volume of published research is proportional to the public health burden of individual cancers. We also explore whether research output is proportional to research funding.
METHODS: Statistics from the Canadian and American cancer societies were used to identify the top ten causes of cancer death in 2013. All journal articles and clinical trials published in 2013 by Canadian or U.S. authors for those cancers were identified. Total research funding in Canada by cancer site was obtained from the Canadian Cancer Research Alliance. Descriptive statistics and Pearson correlation coefficients were used to describe the relationship between research output, cancer mortality, and research funding.
RESULTS: We identified 19,361 publications and 2661 clinical trials. The proportion of publications and clinical trials was substantially lower than the proportion of deaths for lung (41% deaths, 15% publications, 16% clinical trials), colorectal (14%, 7%, 6%), pancreatic (10%, 7%, 5%), and gastroesophageal (7%, 5%, 3%) cancers. Conversely, research output was substantially greater than the proportion of deaths for breast cancer (10% deaths, 29% publications, 30% clinical trials) and prostate cancer (8%, 15%, 17%). We observed a stronger correlation between research output and funding (publications r = 0.894, p < 0.001; clinical trials r = 0.923, p < 0.001) than between research output and cancer mortality (r = 0.363, p = 0.303; r = 0.340, p = 0.337).
CONCLUSIONS: Research output is not well correlated with the public health burden of individual cancers, but is correlated with the relative level of research funding.

Entities:  

Keywords:  Research funding; cancer mortality; cancer policy; clinical trials; public health

Year:  2016        PMID: 27122971      PMCID: PMC4835015          DOI: 10.3747/co.23.2935

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  11 in total

Review 1.  How can payback from health services research be assessed?

Authors:  M Buxton; S Hanney
Journal:  J Health Serv Res Policy       Date:  1996-01

Review 2.  Measuring the impact of medical research: moving from outputs to outcomes.

Authors:  Anthony P Weiss
Journal:  Am J Psychiatry       Date:  2007-02       Impact factor: 18.112

3.  Does Canadian research investment relate to cancer burden?

Authors:  Philip E Branton
Journal:  Lancet Oncol       Date:  2008-02       Impact factor: 41.316

4.  Why the impact factor of journals should not be used for evaluating research.

Authors:  P O Seglen
Journal:  BMJ       Date:  1997-02-15

5.  Representation of cancer in the medical literature--a bibliometric analysis.

Authors:  Ronan W Glynn; Ji Z Chin; Michael J Kerin; Karl J Sweeney
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

6.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

7.  A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding.

Authors:  Ashley J R Carter; Cecine N Nguyen
Journal:  BMC Public Health       Date:  2012-07-17       Impact factor: 3.295

Review 8.  External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer.

Authors:  Christopher M Booth; George Dranitsaris; M Corona Gainford; Scott Berry; Michael Fralick; John Fralick; Joanna Sue; Mark Clemons
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

9.  Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds.

Authors:  N G Burnet; S J Jefferies; R J Benson; D P Hunt; F P Treasure
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

10.  Proposed methods for reviewing the outcomes of health research: the impact of funding by the UK's 'Arthritis Research Campaign'

Authors:  Stephen R Hanney; Jonathan Grant; Steven Wooding; Martin J Buxton
Journal:  Health Res Policy Syst       Date:  2004-07-23
View more
  6 in total

1.  Discrepancies between Canadian cancer research funding and site-specific cancer burden: a spotlight on ten disease sites.

Authors:  A C Coronado; C Finley; K Badovinac; J Han; J Niu; R Rahal
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

2.  Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.

Authors:  Shubham Sharma; J Connor Wells; Wilma M Hopman; Joseph C Del Paggio; Bishal Gyawali; Nazik Hammad; Annette E Hay; Christopher M Booth
Journal:  Curr Oncol       Date:  2021-04-13       Impact factor: 3.677

Review 3.  Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity.

Authors:  J Connor Wells; Adam Fundytus; Shubham Sharma; Wilma M Hopman; Joseph C Del Paggio; Bishal Gyawali; Deborah Mukherji; Nazik Hammad; C S Pramesh; Ajay Aggarwal; Richard Sullivan; Christopher M Booth
Journal:  Curr Oncol       Date:  2022-04-07       Impact factor: 3.109

Review 4.  Research Priorities and Resource Allocation in the Investigation of New Drugs for Cancer in Least Developed Countries.

Authors:  Ricardo Eccard da Silva; Angélica Amorim Amato; Débora Dornelas Belchior Costa Andrade; Alessandra Vanessa Leite E Silva; Marta Rodrigues de Carvalho; Maria Rita Carvalho Garbi Novaes
Journal:  J Oncol       Date:  2018-07-02       Impact factor: 4.375

5.  Integration of conventional cell viability assays for reliable and reproducible read-outs: experimental evidence.

Authors:  Sukant Garg; He Huifu; Sunil C Kaul; Renu Wadhwa
Journal:  BMC Res Notes       Date:  2018-06-22

Review 6.  Anticancer Potential of Lichens' Secondary Metabolites.

Authors:  Zuzana Solárová; Alena Liskova; Marek Samec; Peter Kubatka; Dietrich Büsselberg; Peter Solár
Journal:  Biomolecules       Date:  2020-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.